Lalitha Podila - Concepedia

Author

Lalitha Podila

Also Known As

L. Podila, Lalitha Podila

Publications

399

Citations

H-Index

Concepts

All Affiliations

Lalitha Podila is an author at Boehringer Ingelheim (United States) specializing in natural sciences, drug discovery, and chemical biology.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	91
2	Natural Sciences	2	2	91
3	Biochemistry	2	2	91
4	Chemical Biology	2	2	91
5	Pharmacology	2	2	91

Lalitha Podila

Publications

396

Citations

H-Index

Page 1

	Year	Citations
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria Joe Bentz, Michael O′Connor, Dallas Bednarczyk, Drug Metabolism and Disposition	2013	147
FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY Mitchell E. Taub, Lalitha Podila, Diane Ely, Drug Metabolism and Disposition	2005	124
Differential Selectivity of Efflux Transporter Inhibitors in Caco-2 and MDCK–MDR1 Monolayers: A Strategy to Assess the Interaction of a New Chemical Entity with P-gp, BCRP, and MRP2 Kirsten Mease, Rucha Sane, Lalitha Podila, Journal of Pharmaceutical Sciences Molecular PharmacologyMdck–mdr1 MonolayersDrug TargetBiochemistryNatural Sciences	2012	73
Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients Rucha Sane, Gerhard Steinmann, Qihong Huang, Journal of Pharmacology and Experimental Therapeutics	2014	34
1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335 Rucha Sane, Lalitha Podila, Arvind Mathur, Journal of Hepatology Molecular PharmacologyBiochemistryMedicineNatural SciencesHematology	2011	18

Page 1